Who manufactures Cinqair (Reslizumab)?

Reslizumab bulk supplier for pharma manufacturers

Reslizumab 10mg/ml Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 10mg/ml

Reference Brands: CINQAIR (USA), CINQAERO (EU)

Reslizumab is a Immune Disorder product available as Injection in strengths 10mg/ml. It corresponds to the reference brands CINQAIR (USA), CINQAERO (EU). Verified GMP manufacturers and suppliers on PharmaTradz offer it in bulk for import worldwide, with regulatory documentation and dossier support available on request.

Ask About Access

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Reslizumab? List it or send an offer →

Product Description:

Reslizumab is a humanised monoclonal antibody that binds circulating interleukin-5 and prevents it reaching its receptor on eosinophils. IL-5 is the cytokine that drives eosinophil production, survival and activation, so neutralising it depletes eosinophils — the cells responsible for the airway inflammation in eosinophilic asthma.

It is used as add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adults whose disease is not controlled by inhaled therapy. In trials it reduced exacerbation rates and improved lung function in patients with raised blood eosinophil counts; patients without that phenotype do not benefit, so a blood eosinophil count is required to select candidates. Unlike the other anti-IL-5 agents, which are subcutaneous, reslizumab is given as an intravenous infusion every four weeks, dosed by body weight — which means clinic attendance rather than home administration. It carries a boxed warning for anaphylaxis, so it is given where that can be managed and patients are observed afterwards.

Sourcing notes. Originator biologic, on patent, no biosimilar. Cold chain. The intravenous route and weight-based dosing make it a hospital and infusion-centre product, competing with subcutaneous alternatives that patients can take at home — the main commercial constraint.

How Reslizumab is supplied today, and licensing ahead of patent expiry

Reslizumab is a patented innovator medicine. Where its patents are in force, which today includes most major markets, it can only be supplied by the originator or its licensees, through the routes below. Patents do expire, though, and generic development and licensing deals for post-patent markets start years in advance. If you are developing Reslizumab, hold a dossier for it or want to license it, talk to us.

Named-patient import Where a patient needs the product in a market where it is not registered, named-patient import is the lawful route. It requires the treating physician's documentation and authorisation from the destination regulator. We handle this pathway. Named-patient access

Authorised distribution For registered markets, supply runs through the manufacturer's authorised distribution channel. We can identify the authorised route for your market and tell you whether the product is registered there at all. Innovator sourcing

A genericised alternative Where the clinical requirement is the drug class rather than this specific molecule, there is often an off-patent alternative that is faster to register and materially cheaper. Tell us the indication and target market and we will say plainly whether one exists. Discuss alternatives

Licensing and generic development Patents expire country by country, and in many countries development and dossier filing can start before expiry under research and regulatory-review exemptions. We connect manufacturers developing this molecule, dossier holders, licensees and tech-transfer partners for markets where it is, or will become, off-patent. Partner on this molecule

Ask about Reslizumab supply →

Back to Listing

Frequently Asked Questions

Reslizumab is sold as Cinqair and Cinqaero. It is developed and sold by Teva. PharmaTradz handles enquiries for authorised supply of the originator product, named-patient import where it is not registered, and licensing or development work ahead of patent expiry.